Catalog No.
Product Name
Application
Product Information
Citations
-
Anti-MS4A1/CD47 Antibody
Amulirafusp alfa is an anti-MS4A1/CD47 IgG1κ type human antibody designed to target the MS4A1/CD47 axis. This antibody exhibits key biological activity by antagonizing CD47-mediated immune evasion, thereby enhancing phagocytosis and promoting anti-tumor immunity. It is suitable for applications in cancer immunotherapy research and studies exploring immune cell interactions in various disease models. -
Anti-CD47 Antibody
TQB-2928 is a monoclonal antibody targeting CD47, a prominent regulator of immune evasion in cancer cells. This reagent plays a crucial role in research focused on cancer immunotherapy by blocking the "don't eat me" signal that CD47 transmits to macrophages. TQB-2928 is essential for studying tumor microenvironments, immune responses, and developing therapeutic strategies aimed at enhancing anti-tumor immunity. -
CD47/SIRPα blocking peptide
Pep-20 is a CD47/SIRPα blocking peptide that inhibits the interaction between CD47 and SIRPα, demonstrating KD values of 2.91 μM for human CD47 and 3.63 μM for mouse CD47. With IC50 values of 24.56 μM and 12.03 μM, respectively, for blocking these interactions, Pep-20 exhibits significant anti-tumor activity. This peptide is useful in research applications focused on immune evasion in cancer therapies and interactions within the tumor microenvironment. -
CD47/SIRPα Blocker
NCGC00138783 free base is a selective blocker of the CD47/SIRPα interaction, exhibiting an IC50 of 50 µM. By inhibiting this axis, NCGC00138783 free base promotes immune cell activation, making it a valuable tool for research in cancer immunotherapy and immune modulation studies. Its ability to disrupt CD47 signaling can facilitate investigations into tumor evasion mechanisms and potential therapeutic strategies. -
CD47 Monoclonal Antibody
AO-176 is a humanized anti-CD47 IgG2 monoclonal antibody that targets the CD47-SIRPα interaction to induce tumor phagocytosis. This antibody preferentially binds to tumor cells over normal cells and promotes tumor cell death through a direct mechanism, independent of antibody-dependent cell-mediated cytotoxicity (ADCC). AO-176 exhibits dose-dependent antitumor effects in tumor xenograft models, making it a valuable tool for cancer research, particularly in studies involving lymphoma. -
CD73 Inhibitor
CD73-IN-5 is a potent and selective small molecule inhibitor of CD73, exhibiting an IC50 value of 19 nM. This compound effectively interferes with the enzymatic activity of CD73, which plays a critical role in the production of adenosine in the tumor microenvironment. CD73-IN-5 is utilized in research applications exploring immunomodulation, cancer therapy, and the therapeutic potential of targeting adenosine signaling pathways. -
CD73 Inhibitor
CD73-IN-4 is a selective inhibitor of CD73, functioning through the blockade of adenosine production. With an IC50 of 2.6 nM against human CD73, it demonstrates significant potency in modulating immunosuppressive signals in the tumor microenvironment. This compound is valuable for investigating cancer immunology and exploring therapeutic strategies aimed at enhancing anti-tumor immune responses. -
CD73 Inhibitor
OP-5244 is a potent and orally active inhibitor of CD73, with an IC50 of 0.25 nM. By blocking adenosine production, OP-5244 effectively reverses immunosuppression, making it a valuable tool in cancer research. Its application can aid in the exploration of therapeutic strategies aimed at enhancing anti-tumor immunity. -
Anti-CD73/TGF-β Antibody
Dalutrafusp alfa is a bifunctional antibody that targets CD73 and TGF-β, key components involved in the immunosuppressive pathway. This compound modulates immune responses by inhibiting adenosine production and blocking TGF-β signaling. It is primarily utilized in research focused on tumor immunology and the modulation of immune checkpoints. Its unique mechanism allows for exploration in various therapeutic applications, particularly in cancer treatment and autoimmune diseases. -
NTPDase1 Inhibitor
8-BuS-AMP is an inhibitor of NTPDase1, CD73, and CD39, demonstrating an IC50 of 35 μM and a Ki of 0.292 μM for human NTPDase1, alongside Ki values of 1.19 μM for CD73 and 0.847 μM for CD39. This compound interacts with the substrate-binding sites of NTPDase1 and CD73, effectively preventing the conversion of ATP and AMP to adenosine, which promotes the activation and proliferation of human peripheral T lymphocytes. 8-BuS-AMP exhibits robust enzymatic hydrolysis resistance and metabolic stability, and it has no activity against P2Y1 and P2Y12 receptors. This reagent is suitable for investigations into purinergic signaling pathways and cancer research. -
CD73 Inhibitor
ORIC-533 is a selective, orally active inhibitor of CD73 that operates through an AMP-competitive mechanism, demonstrating potent inhibition of adenosine production with a sub-nanomolar affinity (Ka 0.03 nM). This compound has shown significant promise in the context of multiple myeloma, as it enhances the cytotoxic activity of the immune system against tumor cells by reversing immunosuppression, inducing immunogenic cell death, and activating various immune cells including dendritic cells, T cells, and NK cells, while exhibiting minimal toxicity to normal cells. Furthermore, combined administration of ORIC-533 with daratumumab effectively increases intratumoral CD8+ T cell infiltration and substantially inhibits tumor growth in preclinical models. -
CD73 Inhibitor
CD73-IN-11 is a potent inhibitor of CD73, an enzyme responsible for converting extracellular 5'-AMP into adenosine. By inhibiting CD73, this compound disrupts adenosine production, which is known to induce immunosuppressive effects and can promote tumor proliferation and metastasis. CD73-IN-11 is an essential tool for studying tumor-related diseases and investigating the role of adenosine in cancer biology. -
CD73 Inhibitor
CD73-IN-2 is a potent inhibitor of CD73, demonstrating an IC50 value of 0.09 nM. This compound effectively interferes with the enzymatic activity of CD73, which plays a critical role in the regulation of extracellular adenosine levels. CD73-IN-2 is valuable for research applications focused on immuno-oncology, inflammation, and metabolic diseases. -
CD73 Inhibitor
CD73-IN-19 is a potent CD73 inhibitor, exhibiting a 44% inhibition of CD73 enzymatic activity at 100 μM. It effectively counteracts TCR-induced blockade of T cell proliferation at concentrations of 10 μM and 100 μM, highlighting its role in modulating immune responses. Additionally, CD73-IN-19 has been shown to inhibit hA2A receptor activity in HEK-293 cells, with a Ki value of 3.31 μM. This compound demonstrates potential value in studies related to immune disorders and therapeutic interventions. -
CD73 Inhibitor
CD73-IN-10 is a potent inhibitor of CD73, an enzyme that catalyzes the conversion of extracellular 5'-AMP to adenosine. By inhibiting CD73, this compound can reduce the immunosuppressive effects of adenosine, which play a role in tumor proliferation and metastasis. CD73-IN-10 is valuable for research applications focused on tumor biology and the study of tumor-related diseases. -
CD73 Inhibitor
CD73-IN-13 is a potent inhibitor of CD73, an enzyme implicated in tumor growth, angiogenesis, and metastasis. This compound serves as a valuable tool in the investigation of tumor-related diseases, offering insights into the biochemical pathways associated with cancer progression. Researchers can utilize CD73-IN-13 to explore the therapeutic potential of targeting CD73 in various malignancies. -
CD73 Inhibitor
CD73-IN-8 is a potent inhibitor of CD73, an enzyme responsible for converting extracellular 5'-AMP to adenosine. Elevated levels of adenosine are associated with immunosuppression and enhanced tumor growth and metastasis. CD73-IN-8 is valuable for investigating tumor-related diseases and exploring therapeutic strategies aimed at modulating the adenosine pathway in cancer research. -
CD73 Inhibitor
CD73-IN-14 is a potent and selective inhibitor of CD73, exhibiting an IC50 of 0.17 nM. This compound enhances the recruitment of tumor-infiltrating CD8+ T cells and demonstrates significant anti-tumor activity. Additionally, CD73-IN-14 features an alkyne group that enables its use in click chemistry applications, facilitating copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing partners. This reagent is valuable for studies in immuno-oncology and chemical biology, allowing for the exploration of immune modulation and therapeutic strategies. -
CD73 Inhibitor
ZM522 is a potent CD73 inhibitor with an IC50 value of 0.56 μM. This compound enhances immune activity by elevating interferon-γ (INF-γ) levels and modulating T cell activation. ZM522 is suitable for research applications in immunology and cancer therapy, offering potential insights into immune response mechanisms and therapeutic strategies. -
CD73 Inhibitor
MethADP trisodium is a potent inhibitor of CD73, targeting the enzymatic conversion of ATP to adenosine. This compound plays a crucial role in studies investigating the ATP-adenosine signaling pathway and its implications in cancer, immunology, and inflammatory diseases. MethADP trisodium is instrumental for researchers exploring the modulation of adenosine levels and the effects on immune cell function. -
CD73 Inhibitor
MRS4620 is a potent inhibitor of CD73, exhibiting an inhibitory constant (Ki) of 0.436 nM. This compound is primarily utilized in cancer immunology research, where it can help elucidate the role of CD73 in immune regulation and tumor microenvironment modulation. MRS4620 is valuable for studies aimed at enhancing anti-tumor immunity and understanding the mechanisms of immune evasion in cancer. -
CD73 Inhibitor
CD73-IN-9 is a potent inhibitor of CD73, an enzyme that catalyzes the conversion of extracellular 5'-AMP to adenosine. Elevated adenosine levels are associated with immunosuppressive effects and can promote tumor proliferation and metastasis. This compound is valuable for investigating tumor-related diseases and understanding the role of CD73 in cancer biology. -
OTUD4/CD73 Inhibitor
ST80 is an inhibitor of the OTUD4/CD73 interaction. It effectively decreases the protein level of CD73 and enhances its turnover, which reduces the immune evasion capabilities of tumor cells. This results in significant antitumor efficacy, particularly in the context of immunosuppressive triple-negative breast cancer (TNBC), making ST80 valuable for research in cancer immunotherapy. -
CD73 Inhibitor
PSB-0963 is a selective and competitive inhibitor of ecto-5'-nucleotidase (eN or CD73), exhibiting an inhibition constant (Ki) of 150 nM for rat ecto-5'-nucleotidase. This compound demonstrates high selectivity for eN/CD73 over other ectonucleotidases, such as NTPDases 1-3, and P2Y receptors. PSB-0963 is valuable for research involving cancer biology, particularly in studies focused on immune regulation and tumor microenvironment interactions. -
CD73 Inhibitor
CD73-IN-12 is a potent inhibitor of CD73, an enzyme implicated in tumor growth, angiogenesis, and metastasis. This compound serves as a valuable tool for investigating tumor-related diseases and their underlying mechanisms. Additionally, CD73-IN-12 features an alkyne group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc), making it useful for click chemistry applications in biochemical research. -
CD73 Inhibitor
CD73-IN-18 is a potent inhibitor of extracellular 5-nucleotidase (CD73). By blocking CD73 activity, this compound has shown potential in anti-cancer research, enhancing immune responses against tumors. It serves as a valuable tool in studies aimed at understanding tumor microenvironments and developing novel cancer therapies. -
CD73 Inhibitor
CD73-IN-6 is a potent inhibitor of CD73, a key enzyme involved in the adenosine pathway. This compound is essential for investigating the role of CD73 in cancer biology and its potential therapeutic applications. CD73-IN-6 can be utilized in research focused on tumor immunology and the modulation of the tumor microenvironment, providing insights into cancer progression and treatment strategies. -
CD73 Inhibitor
CD73-IN-7 is a potent inhibitor of CD73, an enzyme that catalyzes the conversion of extracellular 5'-AMP to adenosine. Adenosine plays a critical role in immunosuppression and can facilitate tumor proliferation and metastasis. CD73-IN-7 is suitable for research applications focused on tumor biology and the modulation of immune responses in cancer. -
CD73 Inhibitor
MethADP disodium is a specific inhibitor of CD73, an enzyme involved in the regulation of adenosine signaling. By inhibiting CD73 activity, MethADP disodium can impede the production of adenosine, which plays a critical role in immune suppression and tumor progression. This compound is useful for research applications focusing on cancer immunotherapy, inflammation, and metabolic diseases, providing insights into the modulation of the adenosine pathway. -
CLIP Fragment
CLIP (86-100) is the amino acid fragment of the class II-associated invariant chain peptide, comprising residues 86 to 100. This small self-peptide is a cleavage product that resides within the HLA-II antigen binding groove, playing a pivotal role in the assembly and transport of MHC class II alphabetaIi complexes. It interacts with the class II peptide-binding site, making it essential for understanding MHC class II functionality in immunological research and potential therapeutic applications. -
Anti-Complement C5 Antibody
Ascuprubart is a monoclonal antibody specifically designed to target human Complement C5. By inhibiting the activity of C5, this antibody plays a crucial role in modulating the complement pathway, making it instrumental in research related to immune response and inflammation. Ascuprubart is suitable for applications in studies focused on complement-mediated diseases and therapeutic development. -
COX Inhibitor
Inulicin (1-O-Acetylbritannilactone) is a potent inhibitor of cyclooxygenase (COX) enzymes, specifically targeting COX-2 activity. This compound demonstrates significant biological activity by inhibiting lipopolysaccharide (LPS)-induced production of prostaglandin E2 (PGE2) as well as the expression of COX-2. Additionally, Inulicin suppresses NF-κB activation and its translocation, making it valuable for research applications related to inflammation and cancer. -
COX Inhibitor
COX-1-IN-3 is a selective inhibitor of cyclooxygenase-1 (COX-1), exhibiting non-steroidal anti-inflammatory properties. This compound is valuable for research focused on inflammation and pain management, as it modulates the biosynthesis of prostaglandins. Its specificity for COX-1 makes it an important tool for studying COX-1-related pathways and associated biological processes. -
COX Inhibitor
(S)-Ketorolac is a nonsteroidal anti-inflammatory drug that primarily functions as an inhibitor of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes. This compound is characterized by its potent analgesic and anti-inflammatory properties, making it suitable for pain management in various research applications. Its ability to selectively inhibit COX enzymes positions (S)-Ketorolac as a valuable tool in studies focused on inflammatory processes and pain modulation. -
COX Inhibitor
(±)-Naproxen is a non-steroidal anti-inflammatory drug that inhibits both COX-1 and COX-2 enzymes, exhibiting IC50 values of 8.72 μM and 5.15 μM, respectively. This compound is primarily used in research for its potent anti-inflammatory and analgesic properties. It provides valuable insights into the mechanisms of pain relief and inflammation, making it suitable for various studies in pharmacology and biochemistry. -
sEH/COX-1 Inhibitor
PTUPB is a potent dual inhibitor of soluble epoxide hydrolase (sEH) and cyclooxygenase-1 (COX-1), exhibiting IC50 values of 0.9 nM and 1.26 μM, respectively. This compound is relevant for studies investigating the modulation of inflammatory processes, as it effectively interferes with pathways involving arachidonic acid metabolism. PTUPB serves as a valuable research tool for exploring the therapeutic potential of sEH and COX-1 inhibition in various disease models. -
COX/5-LOX Inhibitor
Phenethyl ferulate is a potent inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (5-LOX), displaying IC50 values of 4.35 μM and 5.75 μM, respectively. This compound exhibits significant anti-inflammatory properties, making it a valuable tool for research into inflammation-related pathways. Its ability to modulate these key enzymes positions it as a promising candidate for studies focused on inflammatory diseases and therapeutic interventions. -
Anti-Inflammatory Agent
Phenyl β-D-glucopyranoside is an anti-inflammatory agent derived from Phellodendron amurense. It exerts its biological activity by inhibiting nitric oxide (NO) production, along with the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). Additionally, Phenyl β-D-glucopyranoside prevents the nuclear translocation of nuclear factor kappa B (NF-κB), leading to the reduced expression of pro-inflammatory cytokines and associated genes. This compound is valuable for researchers studying inflammation and related signaling pathways. -
COX Inhibitor
4-Methylamino antipyrine is a COX inhibitor derived from the active metabolite of Metamizole, a pyrazolone non-steroidal anti-inflammatory drug (NSAID). It exhibits analgesic and antipyretic activities, making it beneficial for alleviating pain and reducing fever. Although its anti-inflammatory properties are relatively weak, 4-Methylamino antipyrine serves as a valuable tool in pharmacological studies involving pain management and inflammatory responses. -
COX-2/iNOS Inhibitor
α-Chaconine is an inhibitor of COX-2 and iNOS, which demonstrates significant anti-inflammatory activity. It effectively reduces the transcriptional expression of COX-2, IL-1β, IL-6, and TNF-α. Additionally, α-Chaconine suppresses LPS-induced expression of iNOS and COX-2 at both the protein and mRNA levels, along with their promoter activities in RAW 264.7 macrophages. This makes α-Chaconine a valuable reagent for studies focused on inflammation and related signaling pathways. -
COX Inhibitor
Sphondin is a cyclooxygenase (COX) inhibitor that effectively reduces the levels of COX-2 protein and prostaglandin E2 (PGE2) release in A549 cells stimulated by IL-1β. This compound's anti-inflammatory properties make it a valuable tool for research into COX-related pathways and the modulation of inflammatory responses in various cellular models. Sphondin can facilitate investigations into therapeutic strategies for inflammatory diseases. -
5-LOX/COX Inhibitor
FPL 62064 is a potent dual inhibitor of 5-lipoxygenase (5-LOX) and cyclooxygenase (COX), exhibiting IC50 values of 3.5 μM and 3.1 μM, respectively, in RBL-1 cells. This compound demonstrates significant anti-inflammatory activity, making it a valuable tool for research into inflammatory pathways and related diseases. Its dual inhibition of leukotriene and prostaglandin synthesis positions FPL 62064 as a pertinent reagent for studies focusing on inflammation and related therapeutic interventions. -
sPLA2/COX-2 Inhibitor
Alminoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that functions as an inhibitor of secretory phospholipase A2 (sPLA2) and cyclooxygenase-2 (COX-2). This compound exhibits potent anti-inflammatory activity, making it useful in research focused on inflammation and pain modulation. Its dual mechanism of action presents opportunities for investigating pathways involved in inflammatory diseases and related therapeutic interventions. -
COX Antagonist
Sudoxicam is a reversible, orally active cyclooxygenase (COX) antagonist classified as a non-steroidal anti-inflammatory drug (NSAID). It exhibits potent anti-inflammatory, anti-edema, and antipyretic activities, making it useful in various research applications related to inflammatory conditions and pain management. Its mechanism of action positions it as a valuable compound for studies investigating the role of COX enzymes in disease processes. -
Anti-inflammatory Agent
Fentiazac is an orally active non-steroidal anti-inflammatory agent and alkanoic acid derivative. It exhibits analgesic, antipyretic, and platelet anti-aggregation properties, making it a valuable tool for investigating inflammatory diseases. Research applications include studies related to rheumatoid arthritis, osteoarthritis, and tendinitis. -
COX Inhibitor
Pelubiprofen is an orally active anti-inflammatory agent that inhibits cyclooxygenase (COX) enzyme activity, displaying IC50 values of 10.66 μM for COX-1 and 2.88 μM for COX-2. It demonstrates notable anti-inflammatory and analgesic properties, making it valuable for research in pain management and inflammation pathways. Pelubiprofen can be utilized in studies examining the roles of COX enzymes in various biological processes and diseases. -
COX
Thromboxane B3 is a prostaglandin analog produced via the cyclooxygenase (COX) metabolic pathway from arachidonic acid. It is synthesized in platelets and vascular endothelial cells through the action of COX and thromboxane synthase. Thromboxane B3 has been identified as a product of human platelets when eicosapentaenoic acid is ingested, indicating its role in modulating vascular functions and platelet aggregation. This compound is relevant for research on cardiovascular diseases and inflammatory processes. -
Anti-inflammatory Agent
Vedaprofen is a COX-1 selective nonsteroidal anti-inflammatory agent (NSAID) that exerts its effects by inhibiting serum TxB2 and exudate PGE2 production. Additionally, it demonstrates the ability to inhibit the sliding clamp (SC) of Escherichia coli (E. coli) with an IC50 of 222 μM. This dual action makes Vedaprofen valuable for research applications focused on inflammation and bacterial mechanisms. -
Nonsteroidal Anti-inflammatory Agent
Flobufen is a nonsteroidal anti-inflammatory agent that functions primarily as an inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (5-LOX). It has been shown to inhibit alloantigen-driven cellular immune responses while enhancing phagocytosis in peritoneal cells. Flobufen is utilized in research focused on immunopathological disorders and demonstrates potential therapeutic effects in conditions such as rheumatoid arthritis. -
COX Inhibitor
Ketorolac-d5 is a deuterated form of Ketorolac, a non-steroidal anti-inflammatory drug that functions as a nonselective inhibitor of cyclooxygenase (COX). It displays inhibitory potency with IC50 values of 20 nM for COX-1 and 120 nM for COX-2. This compound is widely utilized in pharmacological studies to investigate the biochemical pathways of pain and inflammation, as well as in drug metabolism and pharmacokinetic research.
